Zomedica Corp.

Zomedica Corp. (NYSE American: ZOM) is a veterinary health company providing innovative diagnostic and therapeutic products for companion animals — primarily dogs, cats, and horses — through its two primary platforms: the TRUFORMA point-of-care diagnostic analyzer and the ASSISI Loop therapeutic device. According to its website at zomedica.com, Zomedica is committed to helping veterinary practices deliver the highest quality of care to their animal patients through innovative diagnostics and therapeutics that provide better clinical information and treatment options than previously available. The company's TRUFORMA platform uses bulk acoustic wave technology to perform in-clinic diagnostic tests for adrenal, thyroid, and other endocrine diseases in dogs and cats — providing veterinarians with rapid in-clinic test results that guide treatment decisions without requiring send-out laboratory testing that delays diagnosis and treatment.

Zomedica's product platform, described at zomedica.com, encompasses the TRUFORMA point-of-care analyzer — which performs rapid in-clinic testing for cortisol, total T4, TSH, and other biomarkers of endocrine disease in dogs and cats using the company's proprietary biosensor technology — and the ASSISI Loop, a pulsed electromagnetic field (PEMF) therapy device that provides a non-pharmacological, drug-free option for managing pain and inflammation in companion animals and horses. The company's veterinary diagnostic and therapeutic focus addresses the growing spending by pet owners on veterinary care for companion animals — driven by the increasing recognition of pets as family members and the expanding availability of veterinary diagnostic and treatment technologies that mirror those available in human medicine. Zomedica also operates through Pulse Veterinary Technologies, which provides complementary veterinary diagnostic products.

Zomedica Corp. is listed on NYSE American and has pursued the commercial development of its TRUFORMA diagnostic platform and ASSISI Loop therapeutic device through direct sales to veterinary practices, partnerships with veterinary specialty distributors, and educational programs that build veterinarian awareness and adoption of Zomedica's products. According to zomedica.com, the company's growth strategy focuses on expanding TRUFORMA instrument placements in veterinary practices by demonstrating the clinical and economic value of in-clinic endocrine testing, growing its consumable assay revenue from the installed TRUFORMA base, and expanding the ASSISI Loop customer base among companion animal and equine veterinary practices. Zomedica's combination of proprietary veterinary point-of-care diagnostic technology, non-pharmacological pain management therapeutics, companion animal and equine market focus, and NYSE American-listed public company structure establishes it as an innovative veterinary health company serving the growing demand for advanced diagnostic and therapeutic solutions in companion animal medicine.